EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

EDS‐FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials

Sarah K Wise, Nithin D Adappa, Rakesh K Chandra, Greg E Davis, Mahboobeh Mahdavinia, Ramy Mahmoud, John Messina, James N Palmer, Zara M Patel iD, Anju T Peters, Rodney J Schlosser, Raj Sindwani und 2 weitere

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23434 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Sarah K Wise und 13 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Sinusitis, Rhinitis, Paranasal Sinuses, Fluticasone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Optinose US, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The inability of topical medications to reach sinus cavities is a potential reason for lack of efficacy in chronic rhinosinusitis (CRS). One purpose of endoscopic sinus surgery (ESS) is to enable delivery of medications into the sinus cavities. The exhalation delivery system with fluticasone (EDS‐FLU; XHANCE) creates unique biomechanics that enable deposition of intranasal corticosteroid into sinuses and sinus drainage pathways but may have differing efficacy in operated versus unoperated sinuses. Two 24‐week randomized trials (ReOpen1/2) evaluated EDS‐FLU versus EDS‐placebo in patients with CRS, stratified by surgical status.

Methods

Surgery‐naive ( n = 332) and prior‐surgery ( n = 215) patient groups were analyzed as pooled data from ReOpen1/2. Outcome measures (least‐squares mean change from baseline) included combined symptom score (CSS) and congestion score at weeks 4, 8, and 12 and average of percentages of opacified volume (APOV) of ethmoid/maxillary sinuses on CT and Sinonasal Outcome Test 22 (SNOT‐22) total score at week 24.

Results

Baseline scores suggested moderate–severe disease: mean CSS = 5.8; APOV = 67.2%. EDS‐FLU produced significant improvement versus placebo ( p < 0.05): CSS (surgery‐naive, −0.68 vs. −1.42; prior ESS, −0.70 vs. −1.87); congestion (surgery‐naive, −0.24 vs. −0.59; prior ESS, −0.24 vs. −0.69); and SNOT‐22 (surgery‐naive, −7.56 vs. −18.30; prior ESS, −10.72 vs. −18.74). Similar results were observed for APOV ( p < 0.05). No statistically significant difference was observed between surgery subgroups with either EDS‐FLU dose.

Conclusion

EDS‐FLU improved symptoms, sinus opacification, and quality of life in patients with CRS with or without prior ESS, suggesting a role for EDS‐FLU in both populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisRhinitisParanasal SinusesFluticasoneHumansChronic DiseaseMaleFemaleMiddle AgedAdultTreatment OutcomeEndoscopyAdministration, IntranasalAgedRhinosinusitis

Stichwörter der Autor:innen

SNOT‐22chronic rhinosinusitiscomputed tomographycorticosteroid useendoscopic sinus surgeryquality of liferhinosinusitis

Substanzen

Fluticasone

Autor:innen und Institutionen

  • Emory University School of Medicine, Atlanta, Georgia, USA.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • University of Washington, Seattle, Washington, USA.
  • UTHealth Houston, Houston, Texas, USA.
  • Optinose US, Inc., Yardley, Pennsylvania, USA.

ORCID-Profile: Zara M Patel

Förderung

  • Optinose US, Inc.

Zitieren

APA

Wise, S. K., Adappa, N. D., Chandra, R. K., Davis, G. E., Mahdavinia, M., Mahmoud, R., Messina, J., Palmer, J. N., Patel, Z. M., Peters, A. T., Schlosser, R. J., Sindwani, R., Soler, Z. M., & White, A. A. (2024). EDS‐FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23434

Vancouver

Wise SK, Adappa ND, Chandra RK, Davis GE, Mahdavinia M, Mahmoud R, et al. EDS‐FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23434

BibTeX
@article{Wise2024,
  author = {Wise, Sarah K and Adappa, Nithin D and Chandra, Rakesh K and Davis, Greg E and Mahdavinia, Mahboobeh and Mahmoud, Ramy and Messina, John and Palmer, James N and Patel, Zara M and Peters, Anju T and Schlosser, Rodney J and Sindwani, Raj and Soler, Zachary M and White, Andrew A},
  title = {EDS‐FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23434}
}
Kostenlos starten →